Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Eyal Rubin, the Company's Sr. Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email meetings@hcwco.com.
Event Details
Conference: 3rd Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 20, 2025
Location: Nasdaq World Headquarters in New York City (151 W. 43rd Street)
Webcast Details
A webcast of the live presentation will be available at 4:30 pm, Eastern Daylight Time (EDT), via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://journey.ct.events/view/c15f7813-e688-4a3e-911e-358a9c0562b8
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact: Mike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306 mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc-302455102.html
SOURCE Protalix BioTherapeutics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
an hour ago
- Business Upturn
United Rotorcraft Secures First International FIREHAWK® Contract with Colombian Air Force
ENGLEWOOD, CO, Aug. 04, 2025 (GLOBE NEWSWIRE) — United Rotorcraft, a division of Air Methods LLC, is proud to announce its first international contract for the FIREHAWK® helicopter, following a groundbreaking agreement with the Colombian Air Force. This contract marks a significant milestone in the global recognition of the FIREHAWK as a premier aerial firefighting and emergency response asset. Under this agreement, United Rotorcraft will be converting 2 legacy UH-60L Black Hawks to the FIREHAWK configuration. This includes the installation of United Rotorcraft's exclusive high landing gear, a 1,000-gallon DART Aerospace composite belly tank, and an advanced avionics suite designed to improve situational awareness during mission-critical operations. Colombia has a long-standing legacy of leadership in Black Hawk operations. The Colombian Air Force was the first international operator of the Black Hawk and the first to deploy an armed fleet. The Colombian National Police were the first law enforcement agency to operate the Black Hawk. With this new acquisition, the Colombian Air Force becomes the first international operator of the FIREHAWK helicopter. 'Colombia has operated Black Hawk helicopters for 37 years, giving us highly experienced pilots and crewmembers trained specifically for firefighting missions,' said General Luis Carlos Córdoba, Commander of the Colombian Air Force. 'This ensures the successful deployment and operation of the FIREHAWK in our country.' According to official data reported by WRadio on July 11, 2025, more than 7,300 wildfires were recorded in Colombia last year, affecting approximately 290,000 hectares (716,000 acres). 'Wildfires have become a global phenomenon and a growing concern for communities across the world,' said Larry Alexandre, President of United Rotorcraft. 'We are honored to introduce the FIREHAWK's unmatched capabilities to our first international customer and to deliver this life-saving asset to the Colombian Air Force as they strengthen their capacity to protect land, wildlife, and communities from the escalating threat of wildfires. The FIREHAWK has become a benchmark for public agencies across the US Western States, and we are convinced it will become equally popular and effective beyond the US borders, starting with Colombia' This effort was the result of a unique collaboration between the Colombian National Unit for Disaster Risk Management (UNGRD), the Colombian Air Force (FAC), and the Colombian Aeronautical Industry Corporation (CIAC). 'The FIREHAWK is the world's most powerful aerial firefighting platform,' said Carlos Carrillo, Director of UNGRD. 'This technology will enhance emergency response capabilities in moorlands, jungles, savannas, coastal regions, and other hard-to-reach areas.' United Rotorcraft is dedicated to delivering cutting-edge aerial firefighting capabilities through innovation and global collaboration. The introduction of the FIREHAWK into international service represents a major advancement in global wildfire response efforts. ### About United Rotorcraft United Rotorcraft is a leader in mission-critical helicopter completions and modifications, known for designing, manufacturing, and integrating mission-critical equipment for emergency response helicopters. With 30 years of experience in aviation solutions, the company specializes in custom completions for aerial firefighting, search and rescue, and HEMS. Attachment United Rotorcraft Announces First International Contract Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
an hour ago
- Business Upturn
Allied Universal Divests South African Cash Solutions Business to Focus on Core Growth, Streamlined Operations and Employee Safety
IRVINE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) — Allied Universal®, the world's leading security and facility services provider, today announced the divestiture of its South African Cash Solutions ('SA Cash') cash transport business to IZi Africa Properties Ltd. SA Cash was operated under Allied Universal's G4S international brand. The divestiture enables the company to focus on high-growth market segments and streamline international operations. It also highlights its deep commitment to employee safety. The divestiture of SA Cash will be accretive to Allied Universal's earnings and increases free cash flow. Advertisement 'This strategic decision enables us to sharpen our focus on core operations and long-term growth,' said Steve Jones, global chairman and CEO of Allied Universal. 'As we continue to evolve, our commitment to employee safety and well-being remains at the heart of everything we do. We are confident that this transition will benefit both organizations while ensuring continued support for our teams and the clients they serve.' About Allied Universal The world's leading security and facility services provider and trusted partner to more than 400 of the FORTUNE 500, Allied Universal® delivers unparalleled customer relationships, innovative solutions, cutting-edge smart technologies and tailored services that enable clients to focus on their core businesses. With operations in over 100 countries, Allied Universal is the third largest private employer in North America and seventh in the world. Annual revenue is more than $22 billion. There is no greater purpose and responsibility than serving and helping to safeguard customers, communities and people. For more information, visit Media Contact: Kari Garcia Director of Communications – North America Email: [email protected] Newsroom: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
